Consensus Agios Pharmaceuticals, Inc.

Equities

AGIO

US00847X1046

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
29.24 USD +0.41% Intraday chart for Agios Pharmaceuticals, Inc. -3.31% +31.30%

Evolution of the average Target Price on Agios Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

fc065.5N-lsL2UoopMsy2m-NnK5MzBE4ChEXnNwjZBgnZ_pzU.vJ3fiNP4le4262iUn6myp6HxIcPKYkmfg2IQtT487HKHj_r09c7TvCjgQg~0c138bb63f4872e0cd19fa76253f82d3
RBC Trims Price Target on Agios Pharmaceuticals to $42 From $43, Keeps Outperform Rating MT
Goldman Sachs Adjusts Price Target on Agios Pharmaceuticals to $28 From $32, Maintains Neutral Rating MT
JPMorgan Adjusts Agios Pharmaceuticals' Price Target to $32 From $33, Keeps Neutral Rating MT
RBC Lifts Price Target on Agios Pharmaceuticals to $42 From $40 as Phase 2 Trial of Sickle Cell Disease Treatment Meets Primary Endpoint; Outperform Kept MT
Piper Sandler Starts Agios Pharmaceuticals at Overweight With $41 Price Target MT
JPMorgan Chase Adjusts Price Target on Agios Pharmaceuticals to $33 From $48, Maintains Neutral Rating MT
Goldman Sachs Upgrades Agios Pharmaceuticals to Neutral from Sell, Lifts Price Target to $32 From $17 MT
RBC Trims Price Target on Agios Pharmaceuticals to $43 From $44, Maintains Outperform Rating MT
RBC Cuts Price Target on Agios Pharmaceuticals to $44 From $48, Maintains Outperform Rating MT
SVB Securities Upgrades Agios Pharmaceuticals to Outperform from Market Perform, Keeps $33 Price Target MT
RBC Lifts Price Target on Agios Pharmaceuticals to $48 From $47, Maintains Outperform Rating MT
Goldman Sachs Adjusts Agios Pharmaceuticals' Price Target to $16 from $20, Keeps Sell Rating MT
SVB Securities Adjusts Price Target for Agios Pharmaceuticals to $33 From $30, Maintains Market Perform Rating MT
RBC Cuts Price Target on Agios Pharmaceuticals to $47 From $67, Maintains Outperform Rating MT
HC Wainwright Lowers Agios Pharmaceuticals Price Target to $96 From $98, Maintains Buy Rating MT
RBC Raises Price Target on Agios Pharmaceuticals to $67 From $61, Maintains Outperform Rating MT
SVB Leerink Adjusts Agios Pharmaceuticals' Price Target to $30 from $32, Maintains Market Perform Rating MT
HC Wainwright Adjusts Agios Pharmaceuticals' Price Target to $98 from $95, Keeps Buy Rating MT
Canaccord Genuity Adjusts Agios Pharmaceuticals' Price Target to $44 from $52, Maintains Buy Rating MT
Canaccord Genuity Adjusts Agios Pharmaceuticals' Price Target to $52 From $65, Keeps Buy Rating MT
BofA Securities Starts Agios Pharmaceuticals at Buy With $54 Price Target MT
HC Wainwright Adjusts Agios Pharmaceuticals' Price Target to $95 from $93, Keeps Buy Rating MT
AGIOS PHARMACEUTICALS : HC Wainwright Adjusts Agios Pharmaceuticals' Price Target to $93 From $88, Reiterates Buy Rating MT
AGIOS PHARMACEUTICALS : Goldman Sachs Cuts Agios Pharmaceuticals to Sell From Neutral, Price Target to $39 From $58 MT
AGIOS PHARMACEUTICALS : Raymond James Starts Agios Pharmaceuticals at Market Perform MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
29.24 USD
Average target price
40.67 USD
Spread / Average Target
+39.08%
High Price Target
49 USD
Spread / Highest target
+67.58%
Low Price Target
29 USD
Spread / Lowest Target
-0.82%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Agios Pharmaceuticals, Inc.

RBC Capital Markets
Goldman Sachs
JPMorgan Chase
Piper Sandler
SVB Securities LLC
HC Wainwright
SVB Leerink
Canaccord Genuity
BofA Securities
Raymond James
Barclays
J.P. Morgan Chase
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings